Top
Spinal Muscular Atrophy (SMA) Pre-Symptomatic - Healing Genes
1334
post-template-default,single,single-post,postid-1334,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Spinal Muscular Atrophy (SMA) Pre-Symptomatic

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Pre-Symptomatic Study of Intravenous AVXS-101 in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (SPR1NT)

A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2


Phase 3

DESCRIPTION:
Doctors at several research center seek participants with Spinal Muscular Atrophy to trial a new gene replacement therapy intended to restore a functional survival motor neuron gene. This therapy, titled AVXS-101, uses virus shell, genetically engineered to contain the SMN gene DNA, inserts a correct copy of the gene into the patient’s cells. The goal of the treatment is for the patient to achieve adequate permanent production of the SMN protein. Patients with bi-allelic deletion of survival motor neuron 1 gene (SMN1) with 2 or 3 copies of survival motor neuron 2 gene (SMN2). Patients with SMN1 point mutations or the SMN2 gene modifier mutation (c.859G>C) may enroll but will not be included in the efficacy analysis sets.

The study will require admission to the hospital for ~4 days or less, a single infusion of the gene replacement drug, then follow-up until the patient reaches a goal age. The study includes a screening period, a gene replacement therapy period, and a follow-up period. After the End of Study, eligible patients will be asked to rollover into a long-term follow up study.


PATIENT MUST:

  • Be up to 42 days of age
  • Gestational age of 35 to 42 weeks
    • Patients with pre-symptomatic SMA Type 1 as determined by the following features:
      • − 2 copies of SMN2 Patients with 2 copies of SMN2 (n ≥12)
    • Patients with pre-symptomatic SMA Type 2 as determined by the following features:
      • 3 copies of SMN2

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Admission to the hospital and baseline assessments performed.
  3. Single infusion of AVXS-101 drug with in-patient safety monitoring for a minimum of 24 hours post infusion.
  4. Outpatient follow up continues until the patient is 18 or 24 months of age, depending on which type of SMN gene mutation they have. After the End of Study visit, eligible patients will be asked to rollover into a long-term follow up study.

LOCATIONS & CONTACTS:
There are 29 sites conducting this study. Find the study site closest to you.

Contact:
AveXis MedInfo  |  833-828-3947  |  [email protected]
 
SPONSORS
AveXis, Inc.
PRA Health Sciences
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03505099

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader